Pacira BioSciences, Inc.
Congressional Trades
Whale Activity
- Increased88
- New29
- Held45
- Decreased79
- Closed21
- No prior filing16
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 6.9M | $173.7M | increased |
| Doma Perpetual Capital Management LLC | 2.8M | $69.6M | held |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2.4M | $59.4M | decreased |
| DIMENSIONAL FUND ADVISORS LP | 2.3M | $56.9M | increased |
| STATE STREET CORP | 2.1M | $53.7M | increased |
| D. E. Shaw & Co., Inc. | 1.9M | $46.9M | decreased |
| RENAISSANCE TECHNOLOGIES LLC | 1.7M | $41.9M | decreased |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.6M | $40.7M | decreased |
| GOLDMAN SACHS GROUP INC | 1.5M | $37.1M | decreased |
| MORGAN STANLEY | 1.3M | $32.1M | increased |
| AMERICAN CENTURY COMPANIES INC | 1.2M | $30.4M | increased |
| GEODE CAPITAL MANAGEMENT, LLC | 1.1M | $27.3M | decreased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Recent Insider Transactions
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| RIKER LAURENSenior Vice President, Finance | Sale | −6,000 | $36.32 | $218K | Oct 8, 2026 | Form 4 ↗ |
| SLONIN JONATHANChief Medical Officer | Sale | −3,040 | $23.23 | $71K | Aug 17, 2026 | Form 4 ↗ |
| RIKER LAURENSenior Vice President, Finance | Sale | −6,115 | $23.50 | $144K | Jun 11, 2026 | Form 4 ↗ |
| Hirawat SamitDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| CHRISTIE CHRISTOPHERDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| Young AlethiaDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| YANG MICHAEL J.Director | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| BIGAL MARCELODirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| Froimson MarkDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| Brege LauraDirector | Grant / award | +6,405 | $0.00 | $0 | Jun 10, 2026 | Form 4 ↗ |
| WILLIAMS KRISTENChief Administrative Officer | Sale | −10.3K | $22.27 | $228K | Jun 4, 2026 | Form 4 ↗ |
| RIKER LAURENSenior Vice President, Finance | Tax withholding | −3,187 | $22.32 | $71K | Jun 3, 2026 | Form 4 ↗ |
| SLONIN JONATHANChief Medical Officer | Tax withholding | −4,728 | $22.32 | $106K | Jun 3, 2026 | Form 4 ↗ |
| WILLIAMS KRISTENChief Administrative Officer | Tax withholding | −8,528 | $22.32 | $190K | Jun 3, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Sale | −12.9K | $25.16 | $326K | Apr 23, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Option exercise | +12.9K | $16.45 | $213K | Apr 23, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Sale | −1,500 | $25.01 | $38K | Apr 22, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Option exercise | +1,500 | $16.45 | $25K | Apr 22, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Sale | −2,845 | $25.01 | $71K | Apr 21, 2026 | Form 4 ↗ |
| Cross ShawnChief Financial Officer | Option exercise | +2,845 | $16.45 | $47K | Apr 21, 2026 | Form 4 ↗ |
Fund Holders
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF iShares Trust | 2.4M | $60.2M | 0.05% | Jun 30, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.2M | $30.4M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 1.0M | $26.2M | 0.03% | Jun 30, 2026 |
| VANGUARD SMALL-CAP INDEX FUND VANGUARD INDEX FUNDS | 856.2K | $21.7M | 0.01% | Jun 30, 2026 |
| Impax Small Cap Fund IMPAX FUNDS SERIES TRUST I | 750.0K | $19.0M | 2.00% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF American Century ETF Trust | 681.2K | $17.6M | 0.06% | Aug 31, 2026 |
| U.S. SMALL CAP VALUE PORTFOLIO DFA INVESTMENT DIMENSIONS GROUP INC | 570.2K | $15.1M | 0.08% | Jul 31, 2026 |
| VANGUARD SMALL-CAP VALUE INDEX FUND VANGUARD INDEX FUNDS | 542.9K | $13.8M | 0.02% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 453.8K | $11.5M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 432.5K | $11.4M | 0.03% | Jul 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list PCRX's shares (CUSIP 695127100), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
- Vanguard Capital ManagementSCHEDULE 13G/A · passive (13G) · 1.9M shares4.8%
Oct 30, 2026 · ↗ - DOMA2 LLCSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
Oct 13, 2026 · ↗ - The John Templeton FoundationSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
Oct 13, 2026 · ↗ - Pedro EscuderoSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
Oct 13, 2026 · ↗ - DOMA Perpetual Partners GP LLCSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
Oct 13, 2026 · ↗ - DOMA Perpetual LO Equity Master Fund LPSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
Oct 13, 2026 · ↗ - DOMA1 LLCSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
Oct 13, 2026 · ↗ - Doma Perpetual Capital Management LLCSCHEDULE 13D/A · activist (13D) · 0 shares0.0%
Oct 13, 2026 · ↗ - STATE STREET CORPORATIONSCHEDULE 13G · passive (13G) · 2.1M shares5.2%
Aug 7, 2026 · ↗ - Vanguard Portfolio ManagementSCHEDULE 13G · passive (13G) · 2.6M shares6.4%
May 1, 2026 · ↗
Corporate Lobbying
No lobbying filings found naming Pacira BioSciences, Inc. as the client.
Government Contracts
No federal contract awards found for Pacira BioSciences, Inc..
U.S. Patents
No USPTO patent applications found for Pacira BioSciences, Inc..
Annual Financials
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $726.4M | $701.0M | $675.0M | $666.8M | $541.5M |
| Operating income | $19.2M | -$73.4M | $87.7M | $60.0M | $89.9M |
| Net income | $7.0M | -$99.6M | $42.0M | $15.9M | $42.0M |
| Diluted EPS | $0.16 | -$2.15 | $0.89 | $0.34 | $0.92 |
| Operating cash flow | $152.0M | $189.4M | $154.6M | $145.3M | $125.7M |
| Cash and equivalents | $158.5M | $276.8M | $153.3M | $104.1M | $585.6M |
| Total assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M | $1.34B |
| Shareholders' equity | $693.1M | $778.3M | $870.1M | $775.0M | $730.4M |
As Pacira BioSciences, Inc. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗
Stock Splits
No stock splits in PCRX's price history.
Material Events (8-K)
- 8-K · Items 1.01, 1.02, 2.01, 2.04, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01Material agreement · Termination of agreement · Acquisition or dispositionNov 17, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureNov 12, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureNov 5, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureOct 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 4, 2026
EDGAR ↗ - 8-K · Items 1.01, 7.01, 9.01Material agreement · Reg FD disclosureJun 30, 2026
EDGAR ↗ - 8-K · Items 5.02, 5.07, 8.01, 9.01Officer / director change · Shareholder vote · Other eventsJun 11, 2026
EDGAR ↗


